Combined, these observations lead the authors to propose that LIFR-AS1 plays a role in cancer suppression in NSCLC and that LIFR-AS1 as a possible therapeutic target for the treatment of NSCLC. The gene discussed is LIFR; the disease is non-small cell lung carcinoma.